Matches in Nanopublications for { ?s ?p "[Alemtuzumab is a chimeric CD52 monoclonal antibody with activity in CLL patients with fludarabine-refractory disease and 17p deletion.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[Alemtuzumab is a chimeric CD52 monoclonal antibody with activity in CLL patients with fludarabine-refractory disease and 17p deletion.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP687208.RA7VI2k9-sIzN5XrblXljuP0LBLQcMg3gxUubAEW5tU_o130_assertion description "[Alemtuzumab is a chimeric CD52 monoclonal antibody with activity in CLL patients with fludarabine-refractory disease and 17p deletion.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687208.RA7VI2k9-sIzN5XrblXljuP0LBLQcMg3gxUubAEW5tU_o130_provenance.
- NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_assertion description "[Alemtuzumab is a chimeric CD52 monoclonal antibody with activity in CLL patients with fludarabine-refractory disease and 17p deletion.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_provenance.
- NP308438.RAgDgjUfRYsBpfuk-lTYNXgbwHalHqXgjM5l21EsVdVPQ130_assertion description "[Alemtuzumab is a chimeric CD52 monoclonal antibody with activity in CLL patients with fludarabine-refractory disease and 17p deletion.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308438.RAgDgjUfRYsBpfuk-lTYNXgbwHalHqXgjM5l21EsVdVPQ130_provenance.